Probiotic lactobacillus casei strains
OwnerJohn Kevin Collins, Gerald Christopher O'sullivan +3inventors
InventorsJohn Kevin Collins, Gerald Christopher O'sullivan, Liam O'Mahony, Fergus Shanahan, Barry Kiely
Life of this patent
Estimating the term…
Abstract
A Lactobacillus casei strain or a mutant or variant thereof isolated from resected and washed human gastrointestinal tract is significantly immunomodulatory following oral consumption in humans. In particular a Lactobacillus casei strain, AH101, AH104, AH111, AH112 or AH113 or mutants or variants are thereof are useful in the prophylaxis and/or treatment of inflammatory activity especially undesirable gastrointestinal inflammatory activity, such as inflammatory bowel disease or irritable bowel syndrome.
Claims47
A Lactobacillus casei strain or a mutant or variant thereof isolated from resected and washed human gastrointestinal tract.
A Lactobacillus casei strain or a mutant or variant thereof, wherein the Lactobacillus casei strain is significantly immunomodulatory following oral consumption in humans.
A Lactobacillus casei strain selected from any of strains AH101, AH104, AH111, AH112 or AH113 or mutants or variants thereof.
Lactobacillus casei strain AH101 or a mutant or variant thereof.
Lactobacillus casei strain AH104 or a mutant or variant thereof.
Lactobacillus casei strain AH111 or a mutant or variant thereof.
Lactobacillus casei strain AH112 or a mutant or variant thereof.
Lactobacillus casei strain AH113 or a mutant or variant thereof.
A biologically pure culture of a Lactobacillus casei strain selected from any of strains AH101, AH104, AH111, AH112 or AH113.
A method for modifying the levels of IFNγ comprising administering AH101, AH104, AH112 and/or AH113.
A method for reducing the levels of IL-8 comprising administering AH111.
An anti-infective probiotic strain comprising AH101, AH104, AH 111, AH112 and/or AH113.
Dependencies are inferred from the claim text.